The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
RNA editing with CRISPR-Cas13
Abstract
Precise transcriptome engineering: Efficient and precise RNA editing to correct disease-relevant transcripts holds great promise for treating genetic disease. Cox et al. took advantage of the ability of Cas13b, an effector from a type VI CRISPR-Cas system, to target specific RNAs directly (see the Perspective by Yang and Chen). They fused Cas13b with the ADAR2 adenosine deaminase domain and used rational protein engineering to improve the resultant enzyme. These approaches yielded an RNA knockdown and editing platform that allowed efficient and specific RNA depletion and correction in mammalian cells. Science , this issue p. 1019 ; see also p. 996
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CRISPR/Cas13a systems can cleave RNA molecules and emerge as an answer to RNA viruses, although ongoing research focuses on identifying most potent and specific Cas13 variants.
“CRISPR/Cas13a systems also emerge as an answer to RNA viruses do their capacity to cleave RNA molecules, although due to its novelty ongoing research still focuses on identifying the most potent and specific Cas13 variants [173,174].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [173]
The Introduction (page unavailable) says Cas13 enzymes cleave RNA and describes testing Cas13 variants to identify one with efficient, specific RNA knockdown. The Comprehensive Characterization section (page unavailable) includes Cas13a among the variants tested. Our copy does not present Cas13a as an answer to RNA viruses; its reported applications concern RNA knockdown and editing in mammalian cells. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
RNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093
Self-citationTargeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems
Nishida, K., Arazoe, T., Yachie, N., Banno, S., Kakimoto, M., Tabata, M., Mochizuki, M., Miyabe, A., Araki, M., Hara, K. Y., et al. (2016) · Science · doi:10.1126/science.aaf8729 · Cited by 1,349
Flagged first, then by citations
Research works printed but not linked: 32
- 10.1016/j.cell.2014.05.010 · DOI · Paper page
- 10.1016/j.cell.2016.10.044 · DOI
- 10.1016/j.cell.2015.09.038 · DOI · Paper page
- 10.1038/nrg3686 · DOI
- 10.1038/nbt.3803 · DOI · Paper page
- 10.1126/science.aaf5573 · DOI · Paper page
- 10.1016/j.molcel.2015.10.008 · DOI · Paper page
- 10.1038/nrmicro.2016.184 · DOI · Paper page
- 10.1016/j.molcel.2016.12.023 · DOI · Paper page
- 10.1126/science.aam9321 · DOI
- 10.1146/annurev-biochem-060208-105251 · DOI · Paper page
- 10.1038/nature24041 · DOI
- 10.1016/0092-8674(88)90253-X · DOI
- 10.1038/nsmb.3203 · DOI
- Y. Zheng, C. Lorenzo, P. A. Beal, DNA editing in DNA/RNA hybrids by adenosine deaminases that act on RNA. Nucleic Acids Res. 45, 3369–3377 (2017). 28132026
- 10.1073/pnas.1212548109 · DOI
- 10.1017/S135583820101007X · DOI
- 10.1038/srep41478 · DOI
- 10.1073/pnas.1306243110 · DOI
- M. F. Montiel-González, I. C. Vallecillo-Viejo, J. J. Rosenthal, An efficient system for selectively altering genetic information within mRNAs. Nucleic Acids Res. 44, e157 (2016). 27557710
- J. Wettengel, P. Reautschnig, S. Geisler, P. J. Kahle, T. Stafforst, Harnessing human ADAR2 for RNA repair - Recoding a PINK1 mutation rescues mitophagy. Nucleic Acids Res. 45, 2797–2808 (2017). 27907896
- 10.1021/acschembio.5b00711 · DOI
- 10.1021/bi001383g · DOI
- 10.1002/anie.201206489 · DOI
- 10.1038/jid.2010.214 · DOI
- 10.1038/ng.644 · DOI
- 10.1038/nprot.2017.016 · DOI · Paper page
- 10.1186/1471-2105-12-323 · DOI · Paper page
- 10.1002/0471250953.bi1212s49 · DOI
- 10.1093/bioinformatics/btt287 · DOI
- 10.1093/bioinformatics/btr540 · DOI
- J. D. Watson Molecular Biology of the Gene (Pearson Boston ed. 7 2014).
Cited by
Sorted by citations
Base editing: precision chemistry on the genome and transcriptome of living cells
Rees, H. A., & Liu, D. R. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0059-1 · Cited by 1,675
CRISPR-Cas guides the future of genetic engineering
Knott, G. J., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aat5011 · Cited by 1,410
Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors
Konermann, S., Lotfy, P., Brideau, N. J., Oki, J., Shokhirev, M. N., & Hsu, P. D. (2018) · Cell · doi:10.1016/j.cell.2018.02.033 · Cited by 1,164
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Past, present, and future of CRISPR genome editing technologies
Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609
EditR: A Method to Quantify Base Editing from Sanger Sequencing
Kluesner, M. G., Nedveck, D. A., Lahr, W. S., Garbe, J. R., Abrahante, J. E., Webber, B. R., & Moriarity, B. S. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0014 · Cited by 565
Massively parallel Cas13 screens reveal principles for guide RNA design
Wessels, H.-H., Méndez-Mancilla, A., Guo, X., Legut, M., Daniloski, Z., & Sanjana, N. E. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0456-9 · Cited by 418
Precise plant genome editing using base editors and prime editors
Molla, K. A., Sretenovic, S., Bansal, K. C., & Qi, Y. (2021) · Nature Plants · doi:10.1038/s41477-021-00991-1 · Cited by 387
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Structural Basis for the RNA-Guided Ribonuclease Activity of CRISPR-Cas13d
Zhang, C., Konermann, S., Brideau, N. J., Lotfy, P., Wu, X., Novick, S. J., Strutzenberg, T., Griffin, P. R., Hsu, P. D., & Lyumkis, D. (2018) · Cell · doi:10.1016/j.cell.2018.09.001 · Cited by 276
Programmable RNA targeting with the single-protein CRISPR effector Cas7-11
Özcan, A., Krajeski, R., Ioannidi, E., Lee, B., Gardner, A., Makarova, K. S., Koonin, E. V., Abudayyeh, O. O., & Gootenberg, J. S. (2021) · Nature · doi:10.1038/s41586-021-03886-5 · Cited by 263
Self-citationHigh-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects
Tong, H., Huang, J., Xiao, Q., He, B., Dong, X., Liu, Y., Yang, X., Han, D., Wang, Z., Wang, X., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01419-7 · Cited by 230
CRISPR-Based Technologies: Impact of RNA-Targeting Systems
Terns, M. P. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.09.018 · Cited by 168
Loureiro, A., & da Silva, G. J. (2019) · Antibiotics · doi:10.3390/antibiotics8010018 · Cited by 129
RNA-Targeting CRISPR-Cas systems and their applications
Burmistrz, M., Krakowski, K., & Krawczyk-Balska, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031122 · Cited by 125
Design of highly functional genome editors by modeling the universe of CRISPR-Cas sequences
Ruffolo, J. A., Nayfach, S., Gallagher, J., Bhatnagar, A., Beazer, J., Hussain, R., Russ, J., Yip, J., Hill, E., Pacesa, M., et al. (2024) · doi:10.1101/2024.04.22.590591 · Cited by 90
Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J. (2019) · Genes · doi:10.3390/genes10090654 · Cited by 80
Recent advances in gene therapy for neurodevelopmental disorders with epilepsy
Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15168 · Cited by 71
Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells
Méndez-Mancilla, A., Wessels, H.-H., Legut, M., Kadina, A., Mabuchi, M., Walker, J., Robb, G. B., Holden, K., & Sanjana, N. E. (2022) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.07.011 · Cited by 68
Kelley, C. P., Haerle, M. C., & Wang, E. T. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111226 · Cited by 61
Emerging Species and Genome Editing Tools: Future Prospects in Cyanobacterial Synthetic Biology
Gale, G. A. R., Schiavon Osorio, A. A., Mills, L. A., Wang, B., Lea-Smith, D. J., & McCormick, A. J. (2019) · Microorganisms · doi:10.3390/microorganisms7100409 · Cited by 61
Chennakesavulu, K., Singh, H., Trivedi, P. K., Jain, M., & Yadav, S. R. (2022) · Plant Cell Reports · doi:10.1007/s00299-021-02681-w · Cited by 60
Editing the Epigenome to Tackle Brain Disorders
Liu, X. S., & Jaenisch, R. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.10.003 · Cited by 56
A CRISPR way for accelerating cereal crop improvement: Progress and challenges
Basu, U., Riaz Ahmed, S., Bhat, B. A., Anwar, Z., Ali, A., Ijaz, A., Gulzar, A., Bibi, A., Tyagi, A., Nebapure, S. M., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.866976 · Cited by 51
Concerns regarding ‘off-target’activity of genome editing endonucleases
Kadam, U. S., Shelake, R. M., Chavhan, R. L., & Suprasanna, P. (2018) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2018.03.027 · Cited by 47
Li, G., Jin, M., Li, Z., Xiao, Q., Lin, J., Yang, D., Liu, Y., Wang, X., Xie, L., Ying, W., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162809 · Cited by 44
Massively targeted evaluation of therapeutic CRISPR off-targets in cells
Pan, X., Qu, K., Yuan, H., Xiang, X., Anthon, C., Pashkova, L., Liang, X., Han, P., Corsi, G. I., Xu, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31543-6 · Cited by 42
Genome-editing strategies for treating human retinal degenerations
Quinn, J., Musa, A., Kantor, A., McClements, M. E., Cehajic-Kapetanovic, J., MacLaren, R. E., & Xue, K. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.231 · Cited by 41
Kluesner, M. G., Tasakis, R. N., Lerner, T., Arnold, A., Wüst, S., Binder, M., Webber, B. R., Moriarity, B. S., & Pecori, R. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.07.008 · Cited by 36
Intrinsic targeting of host RNA by Cas13 constrains its utility
Li, Z., Li, Z., Cheng, X., Wang, S., Wang, X., Ma, S., Lu, Z., Zhang, H., Zhao, W., Chen, Z., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01109-y · Cited by 31
Sharma, K. K., Palakolanu, S. R., Bhattacharya, J., Shankhapal, A. R., & Bhatnagar-Mathur, P. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.999207 · Cited by 24
Methods for in vitro CRISPR/CasRx-Mediated RNA Editing
Chuang, Y.-F., Wang, P.-Y., Kumar, S., Lama, S., Lin, F.-L., & Liu, G.-S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.667879 · Cited by 21
Deep learning and CRISPR-Cas13d ortholog discovery for optimized RNA targeting
Wei, J., Lotfy, P., Faizi, K., Baungaard, S., Gibson, E., Wang, E., Slabodkin, H., Kinnaman, E., Chandrasekaran, S., Kitano, H., et al. (2021) · doi:10.1101/2021.09.14.460134 · Cited by 67
Optimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13
Burris, B. J. D., Molina Vargas, A. M., Park, B. J., & O'Connell, M. R. (2022) · Methods · doi:10.1016/j.ymeth.2022.08.007 · Cited by 13
Metadata
- Authors
- Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F.
- Affiliations
- Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA 02142, USA.
- ORCID
- Venue
- Science
- Published
- 2017-11-24
- Volume
- 358
- Issue
- 6366
- Pages
- 1019-1027
- ISSN
- 0036-8075
- 1095-9203
- PMC
- PMC5793859
- Cited by
- 1,834
- References
- 6
- Language
- en
- Funders
- National Institutes of Health (award352307, 1R01-HG009761, award352308, 1R01-MH110049, award352309, 1DP1-HL141201, award352311, T32GM007753, award352317, 1F30-CA210382)
- Paul and Daisy Soros Fellowships for New Americans (award352310)
- Howard Hughes Medical Institute (award352313)
- Simons Foundation (award352312)
- Paul G. Allen Family Foundation (award352315)
- New York Stem Cell Foundation (award352314)
- Vallee Foundation (award352316)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review